[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.82.105. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 12, 1986

Interferon's Track Record: Good in Hairy-Cell Leukemia, Fair in Other Hematologie Cancers, Poor in Solid Tumors

JAMA. 1986;256(10):1242-1244. doi:10.1001/jama.1986.03380100016003

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

INTERFERON made its cover debut on the March 31, 1980, issue of Time, with the proclamation, "The Big IF in Cancer Therapy." The accompanying article called it the first biologic agent to show potential in cancer treatment, and asked, "Will its promise be fulfilled?"

Time's question, posed when interferon was available only in minute amounts and at great cost after laborious distillation from white-cell buffy coats or fibroblast monolayers, remains unanswered. But in the six years thence, since recombinant DNA technology has made ample supplies available to basic and clinical researchers, a few more details about the elusive substance have become available.

Interferon is now known to be not one protein, but a family of at least 15 proteins that are secreted by cells infected with viruses or doublestranded RNA or exposed to antigens or mitogens. The interferons bind to receptors of neighboring uninfected cells. The proteins are parceled

×